patient convenience
-
New LEQEMBI Shot Lets Alzheimer’s Patients Skip Clinic Visits
BIIB performance by TradingView Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) announced that the FDA has accepted a review for their new subcutaneous (under-the-skin) version of LEQEMBI, called LEQEMBI IQLIK, for people with early Alzheimer’s disease. The FDA has given it Priority Review, with a decision expected by May 24, 2026. If approved, this version…